E3 ubiquitin-protein ligase Mdm2 (53-60)

E3 ubiquitin-protein ligase Mdm2 (53-60) is a synthetic peptide fragment corresponding to amino acids 53 through 60 of the Mdm2 protein, a crucial regulator in the ubiquitin-proteasome pathway. As a well-characterized segment of the Mdm2 E3 ligase, this peptide plays a significant role in the study of protein-protein interactions, particularly those involving the p53 tumor suppressor pathway. Its defined sequence and structural features make it a valuable tool for researchers investigating the molecular mechanisms of ubiquitination, protein degradation, and cellular homeostasis. The biochemical properties of this peptide enable precise manipulation and observation of Mdm2-related functions in a controlled experimental setting, supporting a wide range of applications in molecular biology and biochemistry research.

Protein-protein interaction studies: The Mdm2 (53-60) peptide is frequently utilized to dissect the interaction dynamics between Mdm2 and its binding partners, most notably the p53 protein. By introducing this defined peptide segment into in vitro assays, researchers can map critical contact points, assess binding affinities, and elucidate the structural determinants of the Mdm2-p53 interface. Such investigations provide insights into the regulatory mechanisms governing cell cycle control and apoptosis, contributing to a deeper understanding of cellular stress responses.

Ubiquitination pathway research: As an integral component of the ubiquitin-proteasome system, Mdm2's activity is central to the targeted degradation of key cellular proteins. The synthetic Mdm2 (53-60) fragment serves as a model substrate or competitive inhibitor in enzymatic assays designed to probe the specificity and kinetics of ubiquitin transfer. Through these studies, scientists can evaluate the functional consequences of sequence alterations, post-translational modifications, or small-molecule modulators on E3 ligase activity, thereby advancing knowledge of protein turnover mechanisms.

Peptide-based inhibitor screening: The defined sequence of the Mdm2 (53-60) peptide provides a template for the rational design and testing of novel inhibitors aimed at modulating Mdm2 function. In screening assays, this peptide can be used to benchmark the efficacy of candidate compounds that disrupt Mdm2-mediated ubiquitination or its interaction with p53. Such applications are integral to the discovery and optimization of research probes targeting the ubiquitin-proteasome pathway in cellular models.

Structural biology and conformational analysis: The availability of the Mdm2 (53-60) peptide enables high-resolution biophysical studies, including NMR spectroscopy and X-ray crystallography, to investigate its conformational properties in isolation or in complex with other proteins. These structural analyses inform on the peptide's secondary structure, flexibility, and binding-induced conformational changes, which are critical for understanding the molecular basis of its function and for guiding the design of mimetics or antagonists.

Peptide modification and functionalization studies: The Mdm2 (53-60) fragment serves as a versatile scaffold for site-directed mutagenesis, labeling, or conjugation experiments. By introducing specific chemical modifications or reporter groups, researchers can track the peptide's localization, monitor its stability, or assess the impact of structural changes on its biological activity. These approaches facilitate the development of advanced analytical tools and expand the experimental repertoire for probing ubiquitin ligase-mediated processes in complex biological systems.

1. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis

2. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

3. Emu oil in combination with other active ingredients for treating skin imperfections

4. The spatiotemporal control of signalling and trafficking of the GLP-1R

5. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction